{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:18:42Z","timestamp":1790065122170,"version":"4.0.1"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["ID 10241"],"award-info":[{"award-number":["ID 10241"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008398","name":"Villum Fonden","doi-asserted-by":"publisher","award":["VKR023179"],"award-info":[{"award-number":["VKR023179"]}],"id":[{"id":"10.13039\/100008398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006197","name":"Fonden til L\u00e6gevidenskabens Fremme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2017,9]]},"abstract":"Abstract<\/jats:title>\n \n \n \n L\u20103,4\u2010Dihydroxyphenylalanine (L\u2010\n DOPA<\/jats:styled-content>\n ) is the most effective drug in the symptomatic treatment of Parkinson's disease, but chronic use is associated with L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia in more than half the patients after 10\u00a0years of treatment. L\u2010\n DOPA<\/jats:styled-content>\n treatment may affect tryptophan metabolism via the kynurenine pathway. Altered levels of kynurenine metabolites can affect glutamatergic transmission and may play a role in the development of L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia. In this study, we assessed kynurenine metabolites in plasma and cerebrospinal fluid of Parkinson's disease patients and controls. Parkinson patients (\n n<\/jats:italic>\n \u00a0=\u00a026) were clinically assessed for severity of motor symptoms (\n UPDRS<\/jats:styled-content>\n ) and L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia (\n UD<\/jats:styled-content>\n ys\n RS<\/jats:styled-content>\n ). Plasma and cerebrospinal fluid samples were collected after overnight fasting and 1\u20132\u00a0h after intake of L\u2010\n DOPA<\/jats:styled-content>\n or other anti\u2010Parkinson medication. Metabolites were analyzed in plasma and cerebrospinal fluid of controls (\n n<\/jats:italic>\n \u00a0=\u00a014), Parkinson patients receiving no L\u2010\n DOPA<\/jats:styled-content>\n (\n n<\/jats:italic>\n \u00a0=\u00a08), patients treated with L\u2010\n DOPA<\/jats:styled-content>\n without dyskinesia (\n n<\/jats:italic>\n \u00a0=\u00a08), and patients with L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia (\n n<\/jats:italic>\n \u00a0=\u00a010) using liquid chromatography\u2010mass spectrometry. We observed approximately fourfold increase in the 3\u2010hydroxykynurenine\/kynurenic acid ratio in plasma of Parkinson's patients with L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia. Anthranilic acid levels were decreased in plasma and cerebrospinal fluid of this patient group. 5\u2010Hydroxytryptophan levels were twofold increased in all L\u2010\n DOPA<\/jats:styled-content>\n \u2010treated Parkinson's patients. We conclude that a higher 3\u2010hydroxykynurenine\/kynurenic acid ratio in plasma may serve as a biomarker for L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia. Longitudinal studies including larger patients cohorts are needed to verify whether the changes observed here may serve as a prognostic marker for L\u2010\n DOPA<\/jats:styled-content>\n \u2010induced dyskinesia.\n <\/jats:p>\n <\/jats:sec>\n \n \n \n \n \n image<\/jats:alt-text>\n <\/jats:graphic>\n <\/jats:boxed-text>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jnc.14104","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T10:36:38Z","timestamp":1497868598000},"page":"756-766","source":"Crossref","is-referenced-by-count":110,"title":["Changes in kynurenine pathway metabolism in Parkinson patients with L\u2010\n DOPA<\/scp>\n \u2010induced dyskinesia"],"prefix":"10.1111","volume":"142","author":[{"given":"Jesper F.","family":"Havelund","sequence":"first","affiliation":[{"name":"Neurobiology Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark"},{"name":"Department of Biochemistry and Molecular Biology VILLUM Center for Bioanalytical Sciences University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9625-1474","authenticated-orcid":false,"given":"Andreas D.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Institute of Regional Health Research University of Southern Denmark Odense Denmark"},{"name":"Focused Research Unit in Neurology Hospital of Southern Jutland Aabenraa Denmark"},{"name":"Department of Neurology Hospital of Southern Jutland S\u00f8nderborg Denmark"},{"name":"Odense Patient data Exploratory Network (OPEN) Odense University Hospital Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Binzer","sequence":"additional","affiliation":[{"name":"Institute of Regional Health Research University of Southern Denmark Odense Denmark"},{"name":"Focused Research Unit in Neurology Hospital of Southern Jutland Aabenraa Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Blaabjerg","sequence":"additional","affiliation":[{"name":"Department of Neurology Odense University Hospital Odense Denmark"},{"name":"Institute of Clinical Research University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels H.H.","family":"Heegaard","sequence":"additional","affiliation":[{"name":"Institute of Clinical Research University of Southern Denmark Odense Denmark"},{"name":"Department of Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark"},{"name":"Department of Autoimmunology & Biomarkers Statens Serum Institut Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Stenager","sequence":"additional","affiliation":[{"name":"Institute of Regional Health Research University of Southern Denmark Odense Denmark"},{"name":"Focused Research Unit in Neurology Hospital of Southern Jutland Aabenraa Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils J.","family":"F\u00e6rgeman","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology VILLUM Center for Bioanalytical Sciences University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-5123","authenticated-orcid":false,"given":"Jan Bert","family":"Gramsbergen","sequence":"additional","affiliation":[{"name":"Neurobiology Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.11.055"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13997"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-016-0289-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.247"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.07.002"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13496"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm304"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604453113"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-160196"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2011.04.028"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000351097","article-title":"Influence of single nucleotide polymorphisms in COMT, MAO\u2010A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease","volume":"13","author":"Cheshire P.","year":"2014","journal-title":"Neurodegener. Dis."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.243"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2016.07.002"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep17799"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06442.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1991.tb03460.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21198"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22341"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2007.08.007"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309676"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007551"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.4137\/IJTR.S16800"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.07.002"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.11"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25555"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.12.009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00246"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/pr500807t"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep13888"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2007.06.044"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.9.1702"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.70010299.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12009"},{"key":"e_1_2_7_35_1","first-page":"1059","article-title":"Anthranilic acid: a potential biomarker and treatment target for schizophrenia","volume":"4","author":"Oxenkrug G.","year":"2016","journal-title":"Ann. Psychiatry Ment. Health"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022482604276"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20988"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077629"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2014.11.015"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02697.x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.09.008"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3257"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-016-1940-y"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.186"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)11636-B"},{"key":"e_1_2_7_46_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JPD-140389","article-title":"Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease","volume":"4","author":"Trupp M.","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3793"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666151215095940"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020200014"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00711A"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjnc.14104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jnc.14104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:19:02Z","timestamp":1696241942000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jnc.14104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/jnc.14104"],"URL":"https:\/\/doi.org\/10.1111\/jnc.14104","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,11]]}}}